Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Saxenda (liraglutide) remains available but is less commonly prescribed for weight management in Canada due to efficacy and cost considerations compared to newer agents
FDA 503A Category 2 (April 2026) On April 15, 2026, the FDA published a 503A bulks list update
and Canada in August, as well as in other markets in September.
The most common side effects associated with GLP-1 agonists include appetite loss, nausea, vomiting, and diarrhea, which are often more pronounced when starting the medication or increasing the dosage (4)(10)(23)
Reports of several medical emergencies reached Switzerland in this context
Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
US$ 24.14
US$ 25.05
US$ 29.25
US$ 29.23
US$ 23.67
US$ 21.72
